

Supporting Information for

Dioxazoles, A New Mild Nitrene Transfer Reagent in Gold Catalysis: Highly Efficient Synthesis of Functionalized Oxazoles

Ming Chen, Ning Sun, Haoyi Chen, Yuanhong Liu*

State Key Laboratory of Organometallic Chemistry

Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences,

345 Lingling Lu, Shanghai 200032, People's Republic of China


Fax: (+86) 021-64166128, E-mail: yhliu@mail.sioc.ac.cn

Contents:	Page
General Methods	S1-S2
Synthesis and characterization of IPrAuNTf ₂	S2
Synthesis and characterization of ynamides 1	S3-S13
Synthesis and characterization of dioxazoles 2	S13-S20
Synthesis and characterization of oxazoles 3 , 6 and 7	S20-S40
Synthesis of compound 13	S40-S42
Trapping of α -imino gold-carbene intermediate	S42-S43
Gram scale synthesis of oxazole 3a	S43
Detection of the released acetone	S43
References	S43-S44
X-ray crystal structure of compounds IPrAuNTf ₂ , 3b and 15	S44-S45
NMR spectra of all new compounds	S46-S205

General Methods. All reactions were carried out under Argon unless noted. DCM and DCE were distilled from CaH₂. Toluene was distilled from sodium and benzophenone. THF was distilled from sodium and benzophenone or purified using Innovative Technology Solvent Purifier (for the synthesis of substrates). MeCN was purified using Innovative Technology Solvent Purifier. Unless noted, all commercial reagents were used without further purification. Ph₃PAuCl,^[1] PPh₃AuNTf₂,^[2] IPrAuNTf₂,^[3] and IPrAu(MeCN)SbF₆^[4] were prepared according to the published methods. 1,3-Bis(2,6-di-isopropylphenyl)imidazole-2-ylidenegold(I) chloride

was purchased from Stream Chemical Company or synthesized by the published method.^[5] (Acetonitrile)[(2-biphenyl)di-*tert*-butylphosphine]gold(I) hexafluoroantimonate was purchased from Aldrich Chemical Company. AgNTf₂ was purchased from Aldrich Chemical Company or prepared by the published method.^[6] Other silver salts were purchased from Stream or Acros Chemical Company. ¹H and ¹³C NMR spectra were recorded at room temperature in CDCl₃ (containing 0.03% TMS), DMSO-*d*₆ (containing 0.03% TMS) or CD₂Cl₂ (containing 0.05% TMS) on Varian XL-400 MHz spectrometer, Agilent 400 MHz NMR spectrometer, or Agilent DDR 600 MHz spectrometer. ¹H NMR spectra was recorded at 400 MHz or 600 MHz, ¹³C NMR spectra was recorded at 100 MHz or 150 MHz. ¹H NMR spectra was recorded with tetramethylsilane (δ = 0.00 ppm) as internal reference; ¹³C NMR spectra was recorded with CDCl₃ (δ = 77.00 ppm), DMSO-*d*₆ (δ = 39.52 ppm) or CD₂Cl₂ (δ = 53.84 ppm) as internal reference. High-resolution mass spectra was obtained by using Waters Micromass GCT mass spectrometer or Agilent Technologies 6224 TOF LC/MS. IR spectra were obtained by using a Nicolet iS10 spectrometer. Melting points were measured using a SGW-4 microscopic melting point apparatus and were uncorrected. Single crystal X-ray diffraction data was collected on Bruker SMART diffractometer with graphite-monochromated Mo-K radiation (λ = 0.71073 Å).

Synthesis of IPrAuNTf₂.^[3]




To a solution of AgNTf₂ (1.03 g, 2.65 mmol) in DCM (30 mL) was added IPrAuCl (1.65 g, 2.65 mmol). The resulting mixture was stirred at room temperature for 4 h and filtered through celite. The pad of celite was further washed with dichloromethane. Then the solvent was reduced under the reduced pressure, and pentane was added resulting in the immediate precipitation of a white solid. The solid was filtered and dried under high vacuum to give IPrAuNTf₂ as a white solid in 88% yield (2.03 g). ¹H NMR (400 MHz, CD₂Cl₂, Me₄Si) δ 7.53 (t, J = 8.0 Hz, 2H), 7.32 (d, J = 8.8 Hz, 4H), 7.31 (s, 2H), 2.49 (sept, J = 6.8 Hz, 4H), 1.29 (d, J = 6.8 Hz, 12H), 1.21 (d, J = 6.8 Hz, 12H); ¹³C NMR (400 MHz, CD₂Cl₂, Me₄Si) δ 168.31, 146.15, 134.01, 131.18, 124.58, 124.39, 119.32 (q, J = 321.4 Hz), 29.29, 24.41, 24.07. Anal. Calcd for C₂₉H₃₆AuF₆N₃O₄S₂: C, 40.23; H, 4.19; N, 4.85. Found: C, 40.21; H, 4.18; N, 4.89.


General procedure for the synthesis of ynamides 1.

Method A : For *N*-alkyl substituted ynamides

Typical procedure for the synthesis of ynamide 1a.




To a dry flask were added *N*-methylmethanesulfonamide (1.09 g, 10 mmol), CuSO₄•5H₂O (249.7 mg, 1.0 mmol), 1,10-phenanthroline (360.4 mg, 2.0 mmol) and K₂CO₃ (2.764 g, 20 mmol). Then toluene (40 mL) and (bromoethynyl)benzene (2.172 g, 12 mmol) were added, and the resulting mixture was stirred at 80 °C for 12 h under an atmosphere of argon. When the reaction was complete, the crude mixture was cooled down to room temperature, filtered through celite and washed with ethyl acetate. After solvent evaporation, the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) to afford compound **1a** (1.82 g, 87%) as a yellow solid.



***N*-Methyl-*N*-(phenylethynyl)methanesulfonamide (1a).** ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.42-7.39 (m, 2H), 7.33-7.28 (m, 3H), 3.29 (s, 3H), 3.11 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 131.43, 128.25, 128.02, 122.25, 82.94, 69.34, 39.13, 36.65. The spectroscopic data are in agreement with that previously reported.^[7]


Method B : For *N*-aryl substituted ynamides

Typical procedure for the synthesis of ynamide 1b.^[8]




To a dry flask were added *N*-phenylmethanesulfonamide (856.1 mg, 5 mmol), K₂CO₃ (1.38 g, 10 mmol) and FeCl₃•6H₂O (135.2 mg, 0.5 mmol). Then anhydrous toluene (20 mL), (bromoethynyl)benzene (1.09 g, 6 mmol) and *N,N'*-dimethylethane-1,2-diamine (DMEDA) (88 mg, 1 mmol) were added. The resulting mixture was stirred at 90 °C for 11 h under an


atmosphere of argon. When the reaction was complete, the crude mixture was cooled down to room temperature, filtered through celite and washed with ethyl acetate. After solvent evaporation, the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) to afford compound **1b** (1.11 g, 82%) as a white solid.




N-Phenyl-N-(phenylethynyl)methanesulfonamide (1b). ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.57 (d, J = 7.6 Hz, 2H), 7.45-7.41 (m, 4H), 7.37-7.33 (m, 1H), 7.30-7.29 (m, 3H), 3.13 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 138.60, 131.48, 129.43, 128.29, 128.26, 128.15, 125.49, 122.15, 81.95, 70.86, 36.73. The spectroscopic data are in agreement with that previously reported.^[9]




4-Methyl-N-phenyl-N-(phenylethynyl)benzenesulfonamide (1c). Method B was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow solid in 51% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.62 (d, J = 8.0 Hz, 2H), 7.40-7.27 (m, 12H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 144.98, 138.87, 132.82, 131.38, 129.47, 129.05, 128.24, 128.22, 127.93, 126.22, 122.53, 82.92, 70.43, 21.66. The spectroscopic data are in agreement with that previously reported.^[9]




4-Bromo-N-phenyl-N-(phenylethynyl)benzenesulfonamide (1d). Method B was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 20:1) afforded the title product as a yellow solid in 89% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.65-7.57 (m, 4H), 7.40-7.29 (m, 10H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 138.56, 134.65, 132.20, 131.51, 129.61, 129.26, 129.23, 128.52, 128.32, 128.21, 126.20, 122.20, 82.35, 70.73. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{15}\text{BrNO}_2\text{S}$ $[\text{M}+\text{H}]^+$: 412.0001, found 412.0001. The spectroscopic data are in agreement with that previously reported.^[9]



4-Nitro-*N*-phenyl-*N*-(phenylethynyl)benzenesulfonamide (1e). Method B was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) afforded the title product as a yellow solid in 66% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.36-8.33 (m, 2H), 7.93-7.90 (m, 2H), 7.40-7.36 (m, 5H), 7.33-7.29 (m, 5H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 150.73, 140.95, 138.14, 131.58, 129.43, 129.42, 128.87, 128.50, 128.39, 126.09, 124.08, 121.74, 81.62, 71.07. IR (neat): 3103, 3062, 2918, 2243, 1606, 1590, 1533, 1489, 1455, 1441, 1401, 1381, 1349, 1308, 1292, 1202, 1174, 1108, 1086, 1080, 1023, 1012, 968, 929, 902, 855, 787, 763, 738, 692, 683 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{20}\text{H}_{14}\text{N}_2\text{O}_4\text{S}$: 378.0674, found 378.0668.




3-(Phenylethynyl)oxazolidin-2-one (1f). Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 4:1 to 2:1) afforded the title product as a white solid in 85% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.45-7.43 (m, 2H), 7.31-7.27 (m, 3H), 4.46 (t, J = 8.8 Hz, 2H), 3.98 (t, J = 8.4 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 155.89, 131.43, 128.22, 128.11, 122.03, 78.90, 71.02, 63.04, 46.91. The spectroscopic data are in agreement with that previously reported.^[7]




***N*-(Phenylethynyl)-*N*-(4-(trifluoromethyl)phenyl)methanesulfonamide (1g).** Method B was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow liquid in 31% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.74-7.67 (m, 4H), 7.47-7.46 (m, 2H), 7.33-7.32 (m, 3H), 3.18 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 141.65, 131.59, 129.74 (q, $^2J_{\text{C-F}}$ = 32.6 Hz), 128.54, 128.37, 126.54 (q, $^3J_{\text{C-F}}$ =


3.8 Hz), 124.88, 123.57 (q, $^1J_{\text{C-F}} = 271$ Hz), 121.65, 80.72, 72.25, 37.28. IR (neat): 3018, 2930, 2241, 1615, 1511, 1415, 1370, 1320, 1211, 1167, 1111, 1066, 1017, 959, 907, 843, 788, 753, 730, 691, 683 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{16}\text{H}_{12}\text{NO}_2\text{F}_3\text{S}$: 339.0541, found 339.0536.



***N*-(4-Methoxyphenyl)-*N*-(phenylethynyl)methanesulfonamide (1h).** Method B was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1 to 3:1) afforded the title product as a yellow solid in 33% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.49-7.41 (m, 4H), 7.30-7.28 (m, 3H), 6.95-6.92 (m, 2H), 3.81 (s, 3H), 3.12 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 159.55, 131.39, 131.13, 128.22, 128.02, 127.40, 122.24, 114.58, 82.39, 70.14, 55.46, 36.35. The spectroscopic data are in agreement with that previously reported.^[10]




***N*-Benzyl-*N*-(phenylethynyl)methanesulfonamide (1i).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 98% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.50-7.47 (m, 2H), 7.42-7.33 (m, 5H), 7.29-7.26 (m, 3H), 4.70 (s, 2H), 2.92 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 134.41, 131.29, 128.92, 128.75, 128.69, 128.22, 127.94, 122.35, 81.90, 71.48, 55.80, 38.85. The spectroscopic data are in agreement with that previously reported.^[7]




***N*-((4-Fluorophenyl)ethynyl)-*N*-methylmethanesulfonamide (1j).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow liquid in 89% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.42-7.37 (m, 2H), 7.03-6.97 (m, 2H), 3.29 (s, 3H), 3.12 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 162.32 (d, $^1J_{\text{C-F}} = 248.2$ Hz), 133.56 (d, $^3J_{\text{C-F}} = 8.4$ Hz), 118.29 (d, $^4J_{\text{C-F}} = 3.4$ Hz), 115.51 (d,


$^2J_{\text{C-F}} = 22.0$ Hz), 82.54, 68.24, 39.08, 36.68. The spectroscopic data are in agreement with that previously reported.^[11]




***N*-((4-Chlorophenyl)ethynyl)-*N*-methylmethanesulfonamide (1k).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow solid in 88% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.34-7.31 (m, 2H), 7.29-7.26 (m, 2H), 3.29 (s, 3H), 3.12 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 133.96, 132.63, 128.59, 120.85, 83.80, 68.44, 39.09, 36.86. The spectroscopic data are in agreement with that previously reported.^[7]




***N*-Methyl-*N*-((4-(trifluoromethyl)phenyl)ethynyl)methanesulfonamide (1l).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow liquid in 86% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.56-7.54 (m, 2H), 7.49-7.47 (m, 2H), 3.32 (s, 3H), 3.14 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 131.06, 129.28 (q, $^2J_{\text{C-F}} = 32.7$ Hz), 126.39, 125.12 (q, $^3J_{\text{C-F}} = 3.8$ Hz), 123.85 (q, $^1J_{\text{C-F}} = 270.2$ Hz), 85.41, 68.60, 39.01, 36.97. The spectroscopic data are in agreement with that previously reported.^[7]



***N*-Methyl-*N*-(*p*-tolylethynyl)methanesulfonamide (1m).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow solid in 92% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.30 (d, $J = 8.0$ Hz, 2H), 7.10 (d, $J = 8.0$ Hz, 2H), 3.27 (s, 3H), 3.10 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 138.21, 131.50, 128.99, 119.08, 82.24, 69.29, 39.13, 36.51, 21.33. The spectroscopic data are in agreement with that previously reported.^[7]



***N*-((4-Methoxyphenyl)ethynyl)-*N*-methylmethanesulfonamide (1n).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1 to 2:1) afforded the title product as a yellow solid in 88% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.38-7.34 (m, 2H), 6.85-6.81 (m, 2H), 3.80 (s, 3H), 3.27 (s, 3H), 3.11 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 159.58, 133.47, 114.12, 113.87, 81.55, 68.99, 55.21, 39.19, 36.47. The spectroscopic data are in agreement with that previously reported.^[7]



To a solution of 1,3,5(10)-estratrien-3-ol-17-one (2.704 g, 10 mmol) in DCM (40 mL) was added pyridine (1.6 mL, 20 mmol). Then Tf_2O (2 mL, 12 mmol, diluted with 20 mL DCM) was added dropwise to the mixture at 0 °C. The resulting solution was warmed up to room temperature and stirred for 2 h. Then the mixture was quenched with saturated ammonium chloride solution, extracted with dichloromethane, and dried over anhydrous Na_2SO_4 . The solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) to afford **s1-10** in 95% isolated yield (3.823 g) as a white solid.


To a solution of the above **s1-10** (2.012 g, 5.0 mmol) in triethylamine (4 mL) and DMF (10 mL) were added ethynyltrimethylsilane (589.3 mg, 6 mmol) and $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (210.6 mg,

0.3 mmol) at room temperature. Then the mixture was stirred at 50 °C for 12 h. After the starting material was consumed, the reaction mixture was quenched with 3 N HCl solution, extracted with dichloromethane, washed with water and brine followed by drying over anhydrous Na₂SO₄. The solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 8:1 to 5:1) to afford compound **s2-1o** (1.576 g, 90%) as a light yellow solid.


To a solution of the above **s2-1o** (1.576 g, 4.5 mmol) in THF (20 mL) was added TBAF 3H₂O (1.562 g, 4.95 mmol) at 0 °C. The resulting solution was warmed up to room temperature and stirred for 1 h. Then the mixture was quenched with water, extracted with dichloromethane, and dried over anhydrous Na₂SO₄. The solvent was evaporated under the reduced pressure and the residue was purified by chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:1) to afford **s3-1o** in 84% isolated yield (1.053 g) as a white solid.

To a solution of **s3-1o** (1.053 g, 3.8 mmol) in acetone (20 mL) were added *N*-bromosuccinimide (811.6 mg, 4.56 mmol) and AgNO₃ (32.3 mg, 0.19 mmol) at room temperature. The mixture was stirred at the same temperature for 8 h. The reaction mixture was diluted with hexanes and filtered through a pad of celite using dichloromethane as an eluent. The filtrate was collected and evaporated under the reduced pressure, the residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate/dichloromethane = 5:1:1) to afford compound **s4-1o** (1.196 g, 88%) as a white solid.


To a dry flask were added *N*-methylethanesulfonamide (432.2 mg, 3.96 mmol), CuSO₄ 5H₂O (82.4 mg, 0.33 mmol), 1,10-phenanthroline (118.9 mg, 0.66 mmol) and K₂CO₃ (912.2 mg, 6.6 mmol). Then anhydrous toluene (15 mL) and **s4-1o** (1.182 g, 3.3 mmol) were added, and the resulting mixture was stirred at 80 °C for 12 h under an atmosphere of argon. When the reaction was complete, the crude mixture was cooled down to room temperature, filtered through celite and washed with ethyl acetate. After solvent evaporation, the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 3:1:1) to afford compound **1o** (1.057 g, 83%) as a light yellow solid.



(8*R*,9*S*,13*S*,14*S*)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-3-yl trifluoromethanesulfonate (s1-1o). ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.35 (d, *J* = 8.8 Hz, 1H), 7.05-7.02 (m, 1H), 7.00 (s, 1H), 2.97-2.93 (m, 2H), 2.52 (dd, *J* = 18.6, 8.4 Hz, 1H), 2.42-2.39 (m, 1H), 2.33-2.27 (m, 1H), 2.20-1.97 (m, 4H), 1.70-1.42 (m, 6H), 0.92 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 220.38, 147.50, 140.21, 139.24, 127.13, 121.15, 118.66 (q, *J* = 319 Hz), 118.21, 50.27, 47.77, 44.00, 37.64, 35.72, 31.39, 29.30, 25.99, 25.59, 21.47, 13.69. The spectroscopic data are in agreement with that previously reported.^[12]




(8*R*,9*S*,13*S*,14*S*)-3-Ethynyl-13-methyl-7,8,9,11,12,13,15,16-octahydro-6*H*-cyclopenta[*a*]phenanthren-17(14*H*)-one (s3-1o). M.p. 173-175 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.27-7.23 (m, 3H), 3.02 (s, 1H), 2.88-2.86 (m, 2H), 2.51 (dd, *J* = 18.8, 9.2 Hz, 1H), 2.40-2.38 (m, 1H), 2.28-2.24 (m, 1H), 2.18-1.94 (m, 4H), 1.67-1.36 (m, 6H), 0.90 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 220.58, 140.68, 136.50, 132.45, 129.27, 125.25, 119.24, 83.63, 76.46, 50.28, 47.77, 44.24, 37.74, 35.69, 31.37, 28.92, 26.13, 25.41, 21.43, 13.69. IR (neat): 3304, 2967, 2932, 2869, 2101, 1733, 1492, 1453, 1430, 1407, 1370, 1253, 1212, 1139, 1080, 1051, 1037, 1008, 944, 921, 904, 884, 824, 781, 737, 708, 652 cm⁻¹; HRMS (ESI) calcd for C₂₀H₂₃O [M+H]⁺: 279.1743, found 279.1740.




(8*R*,9*S*,13*S*,14*S*)-3-(Bromoethynyl)-13-methyl-7,8,9,11,12,13,15,16-octahydro-6*H*-cyclopenta[*a*]phenanthren-17(14*H*)-one (s-1l). M.p. 201-203 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.22-7.19 (m, 3H), 2.89-2.86 (m, 2H), 2.51 (dd, *J* = 18.8, 8.8 Hz, 1H), 2.41-2.38 (m, 1H), 2.30-2.25 (m, 1H), 2.19-1.95 (m, 4H), 1.68-1.38 (m, 6H), 0.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 220.70, 140.69, 136.63, 132.40, 129.22, 125.36, 119.92, 80.01, 50.40,


48.76, 47.87, 44.38, 37.83, 35.79, 31.47, 29.01, 26.23, 25.48, 21.53, 13.78. IR (neat): 2976, 2933, 2873, 2190, 1732, 1496, 1469, 1453, 1426, 1404, 1372, 1339, 1258, 1215, 1139, 1083, 1051, 1005, 968, 913, 834, 824, 788, 750, 707 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{20}\text{H}_{21}\text{OBr}$: 356.0776, found 356.0779.




***N*-Methyl-*N*-(((8*R*,9*S*,13*S*,14*S*)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-3-yl)ethynyl)methanesulfonamide (1o).** M.p. 145-147 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.27-7.17 (m, 3H), 3.29 (s, 3H), 3.12 (s, 3H), 2.89-2.86 (m, 2H), 2.51 (dd, $J = 19.0, 8.8$ Hz, 1H), 2.41-2.39 (m, 1H), 2.30-2.25 (m, 1H), 2.19-1.95 (m, 4H), 1.68-1.38 (m, 6H), 0.91 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 220.73, 140.05, 136.56, 132.01, 128.79, 125.31, 119.48, 82.29, 69.31, 50.36, 47.85, 44.30, 39.17, 37.85, 36.56, 35.76, 31.43, 28.98, 26.23, 25.49, 21.48, 13.75. IR (neat): 3017, 2928, 2858, 2236, 1731, 1452, 1407, 1357, 1259, 1203, 1157, 1120, 1085, 1053, 1008, 963, 889, 869, 823, 784, 772, 713, 657 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{28}\text{NO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 386.1784, found 386.1785.




***N*-Methyl-*N*-(naphthalen-1-ylethynyl)methanesulfonamide (1p).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a brown liquid in 85% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.26 (d, $J = 8.4$ Hz, 1H), 7.80 (d, $J = 8.4$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.61-7.53 (m, 1H), 7.50-7.46 (m, 1H), 7.51-7.45 (m, 1H), 7.39-7.36 (m, 1H), 3.33 (s, 3H), 3.11 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 133.02, 132.94, 129.51, 128.24, 128.16, 126.74, 126.31, 125.82, 125.06, 119.95, 87.64, 67.76, 39.15, 36.69. IR (neat): 3057, 3006, 2931, 2232, 1586, 1507, 1456, 1409, 1353, 1323, 1256, 1208, 1157, 1072, 1039, 1015, 944, 838, 799, 769, 700 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{14}\text{NO}_2\text{S}$ $[\text{M}+\text{H}]^+$: 260.0740, found 260.0740.




***N*-Methyl-*N*-(thiophen-2-ylethynyl)methanesulfonamide (1q).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow liquid in 86% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.28 (dd, J = 5.2, 1.2 Hz, 1H), 7.22 (dd, J = 3.6, 1.2 Hz, 1H), 6.97 (dd, J = 5.2, 3.6 Hz, 1H), 3.28 (s, 3H), 3.11 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 133.29, 128.01, 126.97, 122.21, 86.36, 62.72, 39.12, 36.96. The spectroscopic data are in agreement with that previously reported.^[7]




***N*-(Cyclohex-1-en-1-ylethynyl)-*N*-methylmethanesulfonamide (1r).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow liquid in 93% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 6.09-6.07 (m, 1H), 3.20 (s, 3H), 3.06 (s, 3H), 2.11-2.07 (m, 4H), 1.65-1.56 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 134.83, 119.54, 80.53, 70.87, 39.19, 36.22, 29.41, 25.59, 22.22, 21.37. The spectroscopic data are in agreement with that previously reported.^[13]



***N*-Methyl-*N*-(3-phenylprop-1-yn-1-yl)methanesulfonamide (1s).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow liquid in 81% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.32-7.23 (m, 5H), 3.70 (s, 2H), 3.17 (s, 3H), 3.02 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 136.63, 128.40, 127.59, 126.51, 76.09, 66.78, 38.97, 36.03, 24.52. IR (neat): 3028, 2933, 2256, 1679, 1495, 1454, 1351, 1154, 1075, 1034, 959, 850, 768, 733, 697 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{14}\text{NO}_2\text{S} [\text{M}+\text{H}]^+$: 224.0740, found 224.0741.




***N*-(Hept-1-yn-1-yl)-*N*-methylmethanesulfonamide (1t).** Method A was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a yellow liquid in 91% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 3.16 (s, 3H), 3.03 (s, 3H), 2.27 (t, J = 7.2 Hz, 2H), 1.54-1.50 (m, 2H), 1.38-1.31 (m, 4H), 0.90 (t, J = 7.2 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 74.10, 69.14, 39.12, 35.77, 30.93, 28.49, 22.06, 18.22, 13.89. IR (neat): 2956, 2933, 2860, 2254, 1459, 1353, 1324, 1278, 1156, 1042, 1021, 960, 932, 816, 782, 765 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_9\text{H}_{18}\text{NO}_2\text{S}$ $[\text{M}+\text{H}]^+$: 204.1053, found 204.1055.



***N*-(Cyclopropylethynyl)-*N*-phenylmethanesulfonamide (1u).** Method B was used. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 82% yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.50-7.47 (m, 2H), 7.42-7.38 (m, 2H), 7.34-7.31 (m, 1H), 3.07 (s, 3H), 1.42-1.35 (m, 1H), 0.86-0.72 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 139.07, 129.28, 127.99, 125.40, 75.13, 68.57, 36.24, 8.83, -0.76. The spectroscopic data are in agreement with that previously reported.^[14]


Synthesis of dioxazole 3-phenyl-1,4,2-dioxazol-5-one (2a).^[15]



To a solution of *N*-hydroxybenzamide (1.37 g, 10 mmol) in DCM (100 mL) was added CDI (1,1'-carbonyldiimidazole) (1.62 g, 10 mmol). The resulting solution was stirred at room temperature and for 2 h. Then the mixture was quenched with 1 M HCl, extracted with dichloromethane, washed by water and dried over anhydrous Na_2SO_4 . The solvent was evaporated under the reduced pressure to afford the title product as a white solid in 85% (1.38 g) isolated yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.86-7.84 (m, 2H), 7.68-7.64 (m, 1H),


7.58-7.53 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 163.45, 153.78, 133.74, 129.32, 126.52, 120.00. The spectroscopic data are in agreement with that previously reported.^[15]

Synthesis of 5-phenyl-1,3,2,4-dioxathiazole 2-oxide (**2b**).^[15]



To a solution of thionyl chloride (1.5 mL, 20 mmol) in DCM (20 mL) was added *N*-hydroxybenzamide (685.7 mg, 5 mmol). The resulting solution was stirred at room temperature and for 10 h. Excessive thionyl chloride and solvent were removed under the reduced pressure to afford the title product as a light yellow oil in 89% (818.3 mg) yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.89 (d, J = 7.6 Hz, 2H), 7.59-7.55 (m, 1H), 7.50-7.46 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.07, 132.91, 129.06, 127.89, 120.52. The spectroscopic data are in agreement with that previously reported.^[15]


Synthesis of 5,5-dimethyl-3-phenyl-1,4,2-dioxazole (**2c**).^[15]



To a solution of *N*-hydroxybenzamide (6.857 g, 50 mmol) in DCM (150 mL) were added 2,2-dimethoxypropane (15.623 g, 150 mmol), L(-)-camphorsulfonic acid (11.615 g, 50 mmol). The resulting solution was stirred at room temperature and for 2 h. Then the mixture was quenched with saturated NaHCO_3 solution, extracted with dichloromethane, and dried over anhydrous Na_2SO_4 . The solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) to afford the title product as a colorless oil in 86% (7.628 g) isolated yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.79-7.77 (m, 2H), 7.48-7.39 (m, 3H), 1.68 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.09, 131.14, 128.46, 126.50, 123.52, 115.39, 24.72. The spectroscopic data are in agreement with that previously reported.^[15]


Synthesis of dioxazoles 2d-2p from acyl chloride.

Typical procedure for the synthesis of 3-(4-Fluorophenyl)-5,5-dimethyl-1,4,2-dioxazole (2d).




To a flask were added $\text{NH}_2\text{OH}\cdot\text{HCl}$ (694.9 mg, 10.0 mmol), ethyl acetate (30 mL), H_2O (20 mL) and K_2CO_3 (1.38 g, 10.0 mmol) at 0 °C. After that, 4-fluorobenzoyl chloride (793 mg, 5.0 mmol) dissolved in 10 mL ethyl acetate was added dropwise.^[16] The resulting solution was warmed up to room temperature and stirred for 16 h. The resulting mixture was extracted with ethyl acetate, washed with water and dried over anhydrous Na_2SO_4 . The solvent was evaporated under the reduced pressure and the residue was used directly for the next step without further purification.


To a solution of above 4-fluoro-*N*-hydroxybenzamide in DCM (30 mL) were added 2,2-dimethoxypropane (1.56 g, 15 mmol) and L(-)-camphorsulfonic acid (1.16 g, 5.0 mmol). The resulting solution was stirred at room temperature for 3 h. Then the mixture was quenched with saturated NaHCO_3 solution, extracted with dichloromethane, and dried over anhydrous Na_2SO_4 . The solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a yellow oil in 92% (897.1 mg) yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.79-7.76 (m, 2H), 7.12-7.08 (m, 2H), 1.68 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 164.24 (d, $^1J_{\text{C-F}} = 250.9$ Hz), 157.25, 128.66 (d, $^3J_{\text{C-F}} = 8.7$ Hz), 119.73 (d, $^4J_{\text{C-F}} = 3.0$ Hz), 115.64 (d, $^2J_{\text{C-F}} = 22.0$ Hz), 115.55, 24.56. IR (neat): 3078, 2993, 2938, 1623, 1605, 1513, 1455, 1414, 1375, 1359, 1294, 1220, 1169, 1156, 1099, 1074, 1014, 979, 947, 888, 841, 815, 721, 662 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{11}\text{FNO}_2$ $[\text{M}+\text{H}]^+$: 196.0768, found 196.0769.




3-(4-Chlorophenyl)-5,5-dimethyl-1,4,2-dioxazole (2e). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a colorless oil in 88% overall yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.72-7.70 (m, 2H), 7.40-7.38 (m, 2H), 1.68 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.44, 137.28, 128.86, 127.86, 122.08, 115.89, 24.78. IR (neat): 2991, 2938, 1723, 1620, 1600, 1495, 1453, 1405, 1375, 1360, 1277, 1216, 1168, 1092, 1075, 1015, 978, 946, 890, 834, 815, 762, 737, 716 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{11}\text{ClNO}_2$ $[\text{M}+\text{H}]^+$: 212.0473, found 212.0474.




5,5-Dimethyl-3-(4-(trifluoromethyl)phenyl)-1,4,2-dioxazole (2f). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a colorless oil in 89% overall yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.90 (d, J = 8.0 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 1.71 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.08, 132.68 (q, $^2J_{\text{C-F}}$ = 32.7 Hz), 127.10 (q, $^5J_{\text{C-F}}$ = 1.1 Hz), 126.81, 125.43 (q, $^3J_{\text{C-F}}$ = 3.8 Hz), 123.57 (q, $^1J_{\text{C-F}}$ = 271.0 Hz), 116.35, 24.62. IR (neat): 2995, 2938, 1730, 1619, 1575, 1517, 1456, 1415, 1377, 1321, 1219, 1166, 1125, 1109, 1080, 1063, 1018, 979, 948, 894, 848, 814, 776, 700, 652 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{11}\text{F}_3\text{NO}_2$ $[\text{M}+\text{H}]^+$: 240.0736, found 246.0738.




3-(4-Methoxyphenyl)-5,5-dimethyl-1,4,2-dioxazole (2g). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a colorless oil in 86% overall yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.73-7.69 (m, 2H), 6.93-6.89 (m, 2H), 3.82 (s, 3H), 1.66 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 161.78, 157.94, 128.16, 114.87, 113.85, 55.15, 24.57. IR (neat): 2990, 2938, 2840, 1715, 1607, 1572, 1515, 1457, 1423, 1362, 1307, 1281, 1252, 1215, 1166, 1112, 1078, 1026, 1010, 978, 945, 884, 836, 817, 793, 771, 728, 697, 655 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{14}\text{NO}_3$ $[\text{M}+\text{H}]^+$: 208.0968, found 208.0970.




5,5-Dimethyl-3-(*o*-tolyl)-1,4,2-dioxazole (2h). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a colorless oil in 90% overall yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.70-7.68 (m, 1H), 7.38-7.34 (m, 1H), 7.28-7.23 (m, 2H), 2.57 (s, 3H), 1.68 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.54, 138.49, 131.27, 130.71, 128.58, 125.71, 122.61, 114.09, 24.76, 22.23. IR (neat): 2990, 2926, 2866, 1723, 1611, 1597, 1496, 1455, 1375, 1342, 1286, 1253, 1217, 1170, 1130, 1062, 1050, 978, 946, 886, 823, 764, 741, 720, 679, 659 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 192.1019, found 192.1019.




3-(6-Chloropyridin-3-yl)-5,5-dimethyl-1,4,2-dioxazole (2i). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a light yellow solid in 52% overall yield. M.p. 95-96 $^\circ\text{C}$ ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.76 (d, J = 2.0 Hz, 1H), 8.03 (dd, J = 8.0, 2.4 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 1.71 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 155.62, 153.87, 147.58, 136.34, 124.29, 119.09, 116.75, 24.82. IR (neat): 3059, 2993, 1727, 1621, 1587, 1553, 1458, 1387, 1375, 1345, 1288, 1219, 1171, 1136, 1108, 1078, 1015, 979, 947, 904, 837, 827, 807, 758, 736, 703, 656 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_9\text{H}_{10}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 213.0425, found 213.0427.




3-(Furan-2-yl)-5,5-dimethyl-1,4,2-dioxazole (2j). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a yellow oil in 59% overall yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.56 (d, J = 0.4 Hz, 1H), 6.89 (d, J = 3.6 Hz, 1H), 6.52 (dd, J = 3.2, 1.6 Hz, 1H), 1.68 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 151.75, 145.19, 138.68, 115.95, 113.61, 111.51, 24.50. IR (neat): 2993, 1660, 1621, 1589, 1498, 1465, 1376, 1343, 1305, 1218, 1170, 1141, 1110, 1083, 1019, 979, 948, 895, 852, 813, 758, 739, 656 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_8\text{H}_{10}\text{NO}_3$ $[\text{M}+\text{H}]^+$: 168.0655, found 168.0655.




5,5-Dimethyl-3-(thiophen-2-yl)-1,4,2-dioxazole (2k). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a light yellow oil in 67% overall yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.50 (dd, J = 4.0, 0.8 Hz, 1H), 7.46 (dd, J = 4.8, 0.8 Hz, 1H), 7.08 (dd, J = 4.8, 4.0 Hz, 1H), 1.68 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 154.84, 129.32, 129.23, 127.45, 124.42, 115.86, 24.58. IR (neat): 2993, 1651, 1620, 1589, 1553, 1528, 1460, 1417, 1375, 1345, 1418, 1170, 1136, 1109, 1080, 1059, 1016, 978, 948, 904, 837, 808, 758, 737, 697, 656 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_8\text{H}_{10}\text{NO}_2\text{S}$ $[\text{M}+\text{H}]^+$: 184.0427, found 184.0427.




5,5-Dimethyl-3-(naphthalen-2-yl)-1,4,2-dioxazole (2l). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a white solid in 96% overall yield. M.p. 90-92 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.22 (d, J = 0.4 Hz, 1H), 7.89-7.80 (m, 4H), 7.54-7.47 (m, 2H), 1.72 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.32, 134.41, 132.54, 128.54, 128.38, 127.76, 127.52, 126.84, 126.74, 123.02, 120.83, 115.60, 24.82. IR (neat): 3059, 2989, 2936, 1713, 1615, 1592, 1569, 1510, 1474, 1453, 1393, 1373, 1355, 1253, 1215, 1197, 1166, 1129, 1069, 981, 962, 937, 927, 897, 864, 852, 823, 815, 780, 746, 680, 663 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 228.1019, found 228.1020.




(E)-5,5-Dimethyl-3-styryl-1,4,2-dioxazole (2m). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a white solid in 81% overall yield. M.p. 68-70 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.47-7.44 (m, 2H), 7.38-7.31 (m, 3H), 7.17 (d, J = 16.4 Hz, 1H), 6.60 (d, J = 16.4 Hz, 1H), 1.65 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.33, 137.55, 134.82, 129.39, 128.76, 127.17, 115.26, 109.31, 24.71. IR (neat): 3062, 3030, 2990, 2937, 1717, 1641, 1583, 1571, 1496, 1450, 1372, 1216, 1155, 1074, 1002, 964, 894, 868, 837, 815, 751, 691 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 204.1019, found 204.1021.



(1r,3r,5r,7r)-3'-Methylspiro[adamantane-2,5'-[1,4,2]dioxazole] (2n). The reaction was carried out using *N*-hydroxyacetamide, (1r,3r,5r,7r)-2,2-dimethoxyadamantane (1.0 equiv) and L(-)-Camphorsulfonic acid in DCM. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a white solid in 76% (785 mg) yield. M.p. 77-79 °C ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 2.09 (s, 2H), 2.04-1.94 (m, 7H), 1.85-1.83 (m, 2H), 1.79-1.72 (m, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.54, 118.05, 36.66, 36.04, 34.58, 34.24, 26.56, 26.31, 9.65. IR (neat): 2908, 2855, 1719, 1697, 1673, 1652, 1452, 1392, 1352, 1311, 1290, 1299, 1276, 1233, 1113, 1086, 1057, 1021, 997, 953, 918, 874, 795, 701, 676, 656 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{18}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 208.1332, found 208.1332.




3-Cyclohexyl-5,5-dimethyl-1,4,2-dioxazole (2o). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a colorless oil in 47% overall yield. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 2.40-2.33 (m, 1H), 1.93-1.89 (m, 2H), 1.80-1.76 (m, 2H), 1.69-1.65 (m, 1H), 1.54 (s, 6H), 1.49-1.40 (m, 2H), 1.36-1.23 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 163.14, 113.70, 33.60, 28.81, 25.47, 25.09, 24.35. IR (neat): 2989, 2932, 2856, 1633, 1452, 1452, 1373, 1337, 1216, 1155, 1021, 1007, 989, 955, 895, 872, 859, 819, 754, 733 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{18}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 184.1332, found 184.1333.



3-((3r,5r,7r)-Adamantan-1-yl)-5,5-dimethyl-1,4,2-dioxazole (2p). Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) to afford the title product as a light yellow solid in 84% overall yield. M.p. 73-75 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 2.03 (m, 3H), 1.89 (d, J = 2.8 Hz, 6H), 1.78-1.70 (m, 6H), 1.54 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 166.05, 113.82, 38.72, 36.36, 32.91, 27.57, 24.44. IR (neat): 2989, 2904, 2851, 1728, 1626, 1453, 1372, 1342, 1301, 1217, 1187, 1164, 1103, 1079, 1059, 995, 974, 951, 865, 821, 737, 685 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{22}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 236.1645, found 236.1650.


Synthesis of oxazoles 3.

Typical procedure for the synthesis of *N*-(2,5-Diphenyloxazol-4-yl)-*N*-methylemethanesulfonamide (3a).




To a solution of 5,5-dimethyl-3-phenyl-1,4,2-dioxazole **2c** (63.8 mg, 0.36 mmol) and ynamide **1a** (62.8 mg, 0.3 mmol) in DCE (3 mL) was added IPrAuNTf_2 (13.0 mg, 0.015 mmol). After the reaction mixture was stirred at room temperature for 2 h, the solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether: ethyl acetate = 5:1) to afford **3a** (93.7 mg, 95%) as a white solid. M.p. 175-177 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.08-8.06 (m, 2H), 8.02 (d, J = 8.0 Hz, 2H),

7.50-7.45 (m, 5H), 7.39-7.36 (m, 1H), 3.33 (s, 3H), 3.21 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.32, 145.29, 134.68, 130.79, 128.97, 128.81, 128.79, 126.84, 126.78, 126.23, 125.24, 37.92, 36.86. IR (neat): 3018, 2934, 1616, 1600, 1556, 1494, 1447, 1412, 1364, 1339, 1328, 1283, 1237, 1189, 1154, 1145, 1075, 1065, 1033, 1024, 1003, 994, 972, 965, 948, 928, 848, 783, 764, 732, 703, 694, 676 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 329.0954, found 329.0956.




***N*-(2,5-Diphenyloxazol-4-yl)-*N*-phenylmethanesulfonamide (3b).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 81.4 mg **1b**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at room temperature for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:1) afforded the title product as a white solid in 96% (112.6 mg) isolated yield. M.p. 195-197 $^\circ\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.12-8.11 (m, 2H), 7.99 (d, J = 7.6 Hz, 2H), 7.73 (d, J = 7.6 Hz, 2H), 7.49 (m, 3H), 7.45-7.41 (m, 2H), 7.38-7.33 (m, 3H), 7.31-7.26 (m, 1H), 3.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.19, 145.86, 139.99, 134.13, 130.82, 129.31, 128.99, 128.80, 128.75, 127.75, 126.85, 126.60, 126.32, 125.31, 38.58. IR (neat): 3027, 2924, 2850, 1616, 1596, 1554, 1487, 1448, 1405, 1365, 1350, 1239, 1204, 1163, 1152, 1141, 1092, 1068, 1026, 1015, 965, 951, 927, 910, 833, 784, 762, 726, 710, 693 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{19}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 391.1111, found 391.1111.




***N*-(2,5-Diphenyloxazol-4-yl)-4-methyl-*N*-phenylbenzenesulfonamide (3c).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 104.2 mg **1c**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at room temperature for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 15:1) afforded the title product as a white solid in 72% (101.1 mg) isolated yield. M.p. 188-190 $^\circ\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.09 (d, J = 7.6 Hz,

2H), 8.05-8.03 (m, 2H), 7.71 (d, $J = 8.0$ Hz, 2H), 7.53-7.46 (m, 7H), 7.38-7.34 (m, 1H), 7.27-7.20 (m, 5H), 2.44 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.85, 146.45, 143.89, 139.83, 135.35, 134.38, 130.61, 129.14, 128.97, 128.93, 128.79, 127.52, 127.40, 127.19, 126.93, 126.25, 125.42, 21.64. IR (neat): 3055, 2928, 2854, 1614, 1596, 1553, 1495, 1484, 1447, 1371, 1342, 1248, 1211, 1186, 1159, 1092, 1069, 1024, 1016, 954, 912, 847, 812, 777, 756, 726, 715, 701, 686, 666 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{28}\text{H}_{23}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 467.1424, found 467.1424.




4-Bromo-*N*-(2,5-diphenyloxazol-4-yl)-*N*-phenylbenzenesulfonamide (3d). 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 123.7 mg **1d**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at room temperature for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 15:1:1) afforded the title product as a white solid in 86% (137.3 mg) isolated yield. M.p. 226-228 $^\circ\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.07-8.02 (m, 4H), 7.69-7.46 (m, 10H), 7.36-7.26 (m, 5H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.93, 146.43, 139.43, 137.19, 134.01, 131.56, 130.72, 130.62, 129.06, 128.80, 128.25, 127.85, 127.41, 126.92, 126.69, 126.17, 125.36. IR (neat): 3082, 2966, 1615, 1596, 1575, 1553, 1485, 1447, 1391, 1371, 1360, 1346, 1326, 1281, 1246, 1210, 1183, 1169, 1159, 1147, 1089, 1067, 1010, 947, 915, 833, 821, 777, 764, 741, 700, 688, 676, 651 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{20}\text{BrN}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 531.0373, found 531.0370.




***N*-(2,5-Diphenyloxazol-4-yl)-4-nitro-*N*-phenylbenzenesulfonamide (3e).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 113.5 mg **1e**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at room temperature for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:1) afforded the title product as a yellow


solid in 77% (115.3 mg) isolated yield. M.p. 248-250 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.34-8.31 (m, 2H), 8.06-8.04 (m, 2H), 8.02-7.99 (m, 4H), 7.52-7.48 (m, 7H), 7.42-7.38 (m, 1H), 7.32-7.26 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.18, 150.36, 146.62, 143.82, 139.10, 133.67, 130.98, 130.48, 129.32, 129.30, 128.96, 128.93, 128.28, 127.40, 126.82, 126.55, 126.22, 125.45, 123.50. IR (neat): 3110, 3066, 3034, 1611, 1588, 1551, 1526, 1486, 1448, 1404, 1370, 1349, 1325, 1310, 1244, 1209, 1170, 1144, 1089, 1071, 1015, 950, 916, 857, 778, 765, 747, 739, 701, 690, 683, 652 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{20}\text{N}_3\text{O}_5\text{S}$ $[\text{M}+\text{H}]^+$: 498.1118, found 498.1116.




3-(2,5-Diphenyloxazol-4-yl)oxazolidin-2-one (3f). 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 56.2 mg **1f**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at room temperature for 4 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 89% (82.1 mg) isolated yield. M.p. 206-208 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.07-8.05 (m, 2H), 7.73 (d, $J = 8.4$ Hz, 2H), 7.47-7.43 (m, 5H), 7.37-7.34 (m, 1H), 4.57 (t, $J = 7.6$ Hz, 2H), 4.10 (t, $J = 8.0$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 158.62, 156.23, 143.44, 131.26, 130.73, 128.77, 128.69, 127.01, 126.76, 126.23, 125.19, 62.87, 46.02. IR (neat): 3058, 2924, 2850, 1753, 1619, 1598, 1557, 1485, 1452, 1445, 1406, 1330, 1242, 1212, 1160, 1123, 1094, 1071, 1042, 1027, 977, 953, 934, 920, 839, 776, 765, 749, 704, 696, 688, 676 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{15}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 307.1077, found 307.1079.




***N*-(2,5-Diphenyloxazol-4-yl)-*N*-(4-(trifluoromethyl)phenyl)methanesulfonamide (3g).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 101.8 mg **1g**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 96% (131.6 mg) isolated yield. M.p. 175-177 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.14-8.12 (m, 2H), 7.96-7.94 (m, 2H), 7.83 (d, *J* = 8.8 Hz, 2H), 7.63 (d, *J* = 8.8 Hz, 2H), 7.51-7.50 (m, 3H), 7.46-7.42 (m, 2H), 7.37-7.33 (m, 1H), 3.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.57, 146.34, 143.12, 133.24, 131.05, 129.30, 129.27 (q, ²*J*_{C-F} = 32.7 Hz), 128.88, 126.65, 126.47 (q, ³*J*_{C-F} = 3.8 Hz), 126.37, 126.29, 126.14, 125.26, 123.68 (q, ¹*J*_{C-F} = 271 Hz), 39.00. IR (neat): 3078, 3030, 2930, 1613, 1554, 1513, 1488, 1447, 1419, 1365, 1352, 1325, 1249, 1213, 1186, 1162, 1144, 1121, 1113, 1092, 1069, 1026, 1015, 980, 968, 926, 895, 858, 843, 835, 782, 768, 760, 723, 709, 700, 688, 669 cm⁻¹; HRMS (ESI) calcd for C₂₃H₁₈F₃N₂O₃S [M+H]⁺: 459.0985, found 459.0986.



***N*-(2,5-Diphenyloxazol-4-yl)-*N*-(4-methoxyphenyl)methanesulfonamide (3h).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 90.4 mg **1h**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1 to 3:1) afforded the title product as a white solid in 99% (125.1 mg) isolated yield. M.p. 191-193 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.12-8.09 (m, 2H), 8.02-8.00 (m, 2H), 7.67 (d, *J* = 9.6 Hz, 2H), 7.50-7.41 (m, 5H), 7.34-7.31 (m, 1H), 6.88 (d, *J* = 9.2 Hz, 2H), 3.74 (s, 3H), 3.32 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 159.06, 158.07, 145.49, 134.44, 132.57, 130.74, 128.90, 128.75, 128.69, 128.63, 126.83, 126.64, 126.24, 125.26, 114.40, 55.33, 38.20. IR (neat): 3014, 2924, 2850, 1616, 1604, 1556, 1505, 1486, 1468, 1448, 1366, 1346, 1323, 1293, 1243, 1211, 1164, 1154, 1108, 1071, 1030, 1015, 978, 953, 928, 839, 831, 794, 780, 757, 717, 698, 688 cm⁻¹; HRMS (ESI) calcd for C₂₃H₂₁N₂O₄S [M+H]⁺: 421.1217, found 421.1218.




***N*-Benzyl-*N*-(2,5-diphenyloxazol-4-yl)methanesulfonamide (3i).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 85.6 mg **1i**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 6:1) afforded the title product as a white solid in 85% (103.1 mg) isolated yield. M.p. 154-156 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.06-8.03 (m, 2H), 7.76-7.74 (m, 2H), 7.48-7.45 (m, 3H), 7.32-7.22 (m, 5H), 7.12-7.08 (m, 3H), 4.81 (s, 2H), 3.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.24, 147.16, 134.53, 132.61, 130.71, 129.31, 128.81, 128.78, 128.27, 128.19, 128.00, 126.90, 126.41, 126.21, 125.45, 54.74, 38.38. IR (neat): 3002, 2926, 2850, 1620, 1556, 1496, 1487, 1460, 1448, 1391, 1356, 1346, 1320, 1221, 1156, 1089, 1069, 1054, 1037, 1024, 959, 925, 915, 856, 821, 774, 757, 730, 701, 687 cm⁻¹; HRMS (ESI) calcd for C₂₃H₂₁N₂O₃S [M+H]⁺: 405.1267, found 405.1269.




***N*-(5-(4-fluorophenyl)-2-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3j).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 68.2 mg **1j**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 4 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 6:1) afforded the title product as a white solid in 89% (92.1 mg) isolated yield. M.p. 182-184 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.06-7.99 (m, 4H), 7.49-7.47 (m, 3H), 7.17-7.12 (m, 2H), 3.32 (s, 3H), 3.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 162.86 (d, ¹J_{C-F} = 248.6 Hz), 158.28, 144.59, 134.29 (d, ⁵J_{C-F} = 1.9 Hz), 130.84, 128.82, 127.33 (d, ³J_{C-F} = 8.4 Hz), 126.71, 126.21, 123.10 (d, ⁴J_{C-F} = 3.4 Hz), 115.92 (d, ²J_{C-F} = 21.6 Hz), 37.89, 36.66. IR (neat): 3030, 3006, 2926, 2854, 1626, 1604, 1591, 1556, 1509, 1487, 1448, 1415, 1367, 1339, 1325, 1304, 1232, 1190, 1160, 1151, 1089, 1065, 1023,

1004, 973, 947, 930, 859, 839, 811, 776, 765, 739, 715, 694 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{FN}_2\text{O}_3\text{S} [\text{M}+\text{H}]^+$: 347.0860, found 347.0862.




***N*-(5-(4-Chlorophenyl)-2-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3k).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 73.1 mg **1k**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 85% (92.5 mg) isolated yield. M.p. 184-186 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.06-8.03 (m, 2H), 7.95-7.93 (m, 2H), 7.49-7.47 (m, 3H), 7.42-7.40 (m, 2H), 3.32 (s, 3H), 3.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.51, 144.35, 134.96, 134.74, 130.93, 129.00, 128.82, 126.60, 126.47, 126.25, 125.25, 37.85, 36.65. IR (neat): 3006, 2925, 2850, 1622, 1563, 1491, 1452, 1405, 1365, 1341, 1320, 1288, 1245, 1183, 1155, 1094, 1067, 1013, 998, 974, 964, 950, 929, 854, 826, 780, 767, 735, 714, 692 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{ClN}_2\text{O}_3\text{S} [\text{M}+\text{H}]^+$: 363.0565, found 363.0566.




***N*-Methyl-*N*-(2-phenyl-5-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methanesulfonamide (3l).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 83.2 mg **1l**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 9 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 83% (99.2 mg) isolated yield. M.p. 162-164 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.13 (d, J = 8.4 Hz, 2H), 8.09-8.07 (m, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.51-7.50 (m, 3H), 3.35 (s, 3H), 3.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 159.20, 143.88, 136.30, 131.21, 130.34 (q, ² $J_{\text{C-F}}$ = 32.6 Hz), 130.04 (q, ⁵ $J_{\text{C-F}}$ = 1.5 Hz), 128.90, 126.43, 126.40, 125.73 (q, ³ $J_{\text{C-F}}$ = 3.8 Hz),

125.32, 123.84 (q, $^1J_{C-F} = 271$ Hz), 37.85, 36.63. IR (neat): 3074, 2934, 1620, 1552, 1485, 1449, 1413, 1369, 1346, 1322, 1254, 1163, 1146, 1006, 1066, 1013, 1002, 959, 928, 847, 779, 764, 747, 728, 702, 692, 684 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{F}_3\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 397.0828, found 397.0830.




***N*-Methyl-*N*-(2-phenyl-5-(*p*-tolyl)oxazol-4-yl)methanesulfonamide (3m).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 67.0 mg **1m**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 88% (90.8 mg) isolated yield. M.p. 157-159 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.06-8.03 (m, 2H), 7.90 (d, $J = 8.4$ Hz, 2H), 7.48-7.45 (m, 3H), 7.25 (d, $J = 8.0$ Hz, 2H), 3.31 (s, 3H), 3.19 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.94, 145.50, 139.07, 134.00, 130.61, 129.44, 128.74, 126.89, 126.13, 125.17, 123.99, 37.85, 36.80, 21.36. IR (neat): 3026, 2932, 2850, 1606, 1555, 1509, 1486, 1451, 1409, 1367, 1338, 1241, 1202, 1184, 1153, 1098, 1063, 1025, 999, 972, 857, 840, 820, 784, 762, 735, 714, 704, 693 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 343.1111, found 343.1113.




***N*-(5-(4-Methoxyphenyl)-2-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3n).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 71.8 mg **1n**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 50 °C for 4 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 3:1) afforded the title product as a white solid in 71% (76.5 mg) isolated yield. M.p. 203-205 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.05-8.03 (m, 2H), 7.95 (d, $J = 8.8$ Hz, 2H), 7.48-7.46 (m, 3H), 6.99 (d, $J = 8.8$ Hz, 2H), 3.84 (s, 3H), 3.31 (s, 3H), 3.19


(s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 160.12, 157.68, 145.52, 133.17, 130.56, 128.78, 127.01, 126.91, 126.11, 119.55, 114.26, 55.29, 37.94, 36.78. IR (neat): 3078, 3013, 2922, 2847, 1621, 1607, 1573, 1556, 1510, 1487, 1449, 1429, 1370, 1343, 1332, 1298, 1283, 1254, 1188, 1175, 1166, 1146, 1117, 1093, 1067, 1029, 993, 953, 919, 853, 831, 796, 777, 764, 736, 717, 694, 686 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$: 359.1060, found 359.1061.




***N*-Methyl-*N*-(5-((8*R*,9*S*,13*S*,14*S*)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-3-yl)-2-phenyloxazol-4-yl)methanesulfonamide (3o).** 0.3 mmol scale. Following the typical procedure, 63.8 mg 5,5-dimethyl-3-phenyl-1,4,2-dioxazole **2c**, 115.7 mg **1o**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at $80\text{ }^\circ\text{C}$ for 2 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: chloromethane = 2:1:1) afforded the title product as a white solid in 97% (146.7 mg) isolated yield. M.p. $214\text{--}216\text{ }^\circ\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.07–8.05 (m, 2H), 7.80 (d, $J = 8.0\text{ Hz}$, 1H), 7.69 (s, 1H), 7.48–7.47 (m, 3H), 7.37 (d, $J = 8.0\text{ Hz}$, 1H), 3.32 (s, 3H), 3.20 (s, 3H), 3.00–2.96 (m, 2H), 2.50 (dd, $J = 18.8, 8.8\text{ Hz}$, 1H), 2.44–2.40 (m, 1H), 2.33–2.28 (m, 1H), 2.16–1.96 (m, 4H), 1.66–1.44 (m, 6H), 0.91 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 220.66, 157.95, 145.30, 140.82, 136.87, 134.15, 130.60, 128.71, 126.79, 126.08, 125.73, 125.50, 124.20, 122.70, 50.29, 47.77, 44.30, 37.81, 37.76, 36.73, 35.68, 31.38, 29.33, 26.20, 25.39, 21.41, 13.67. IR (neat): 3009, 2930, 2854, 2242, 1733, 1622, 1557, 1501, 1450, 1407, 1374, 1344, 1260, 1155, 1085, 1054, 1008, 963, 890, 869, 840, 822, 776, 762, 735, 713, 699, 688 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{33}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$: 505.2156, found 505.2153.




***N*-Methyl-*N*-(5-(naphthalen-1-yl)-2-phenyloxazol-4-yl)methanesulfonamide (3p).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 77.8 mg **1p**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 88% (100.2 mg) isolated yield. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.13-8.07 (m, 3H), 8.00 (d, *J* = 7.2 Hz, 1H), 7.94-7.88 (m, 2H), 7.58-7.50 (m, 3H), 7.47-7.45 (m, 3H), 3.194 (s, 3H), 3.188 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 159.24, 145.34, 137.05, 133.64, 131.00, 130.79, 130.41, 128.85, 128.82, 128.56, 126.95, 126.92, 126.22, 126.15, 125.32, 125.07, 123.62, 38.17, 37.45. IR (neat): 3050, 3006, 2930, 1701, 1612, 1591, 1558, 1508, 1487, 1449, 1401, 1343, 1324, 1270, 1241, 1152, 1050, 1024, 958, 859, 803, 775, 760, 733, 712, 690 cm⁻¹; HRMS (ESI) calcd for C₂₁H₁₉N₂O₃S [M+H]⁺: 379.1111, found 379.1113.




***N*-Methyl-*N*-(2-phenyl-5-(thiophen-2-yl)oxazol-4-yl)methanesulfonamide (3q).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 64.6 mg **1q**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:0 to 3:1:1) afforded the title product as a yellow solid in 94% (94.4 mg) isolated yield. M.p. 198-200 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.04 (s, 2H), 7.64 (s, 1H), 7.47-7.40 (m, 4H), 7.11 (s, 1H), 3.32 (s, 3H), 3.18 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 157.97, 142.56, 133.19, 130.78, 128.80, 127.71, 127.64, 127.00, 126.64, 126.22, 125.90, 37.63, 36.81. IR (neat): 3018, 2926, 1625, 1552, 1489, 1452, 1435, 1363, 1342, 1317, 1243, 1227, 1178, 1156, 1142, 4087, 1072, 1059, 1038, 1020, 961, 856, 940, 781, 763, 701, 691 cm⁻¹; HRMS (ESI) calcd for C₁₅H₁₅N₂O₃S₂ [M+H]⁺: 335.0519, found 335.0520.




***N*-(5-(Cyclohex-1-en-1-yl)-2-phenyloxazol-4-yl)-*N*-methylnmethanesulfonamide (3r).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 64.0 mg **1r**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 50 °C for 4 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 50% (49.9 mg) isolated yield. M.p. 198-200 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.98-7.96 (m, 2H), 7.45-7.44 (m, 3H), 6.62-6.60 (m, 1H), 3.26 (s, 3H), 3.14 (s, 3H), 2.55-2.54 (m, 2H), 2.27-2.25 (m, 2H), 1.79-1.73 (m, 2H), 1.69-1.64 (m, 2H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 157.38, 147.02, 133.00, 130.45, 128.72, 128.55, 127.13, 126.07, 124.95, 38.27, 36.71, 25.52, 24.41, 22.14, 21.67. IR (neat): 3018, 2933, 2874, 2826, 1637, 1587, 1556, 1490, 1447, 1432, 1393, 1338, 1326, 1287, 1226, 1161, 1150, 1087, 1064, 1050, 1024, 984, 966, 929, 908, 853, 835, 809, 782, 764, 729, 705, 691 cm⁻¹; HRMS (ESI) calcd for C₁₇H₂₁N₂O₃S [M+H]⁺: 333.1267, found 333.1270.




***N*-(5-Benzyl-2-phenyloxazol-4-yl)-*N*-methylnmethanesulfonamide (3s).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 67.0 mg **1s**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 6 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a colorless liquid in 70% (72.0 mg) isolated yield. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.94-7.92 (m, 2H), 7.44-7.40 (m, 3H), 7.33-7.30 (m, 4H), 7.28-7.22 (m, 1H), 4.15 (s, 2H), 3.25 (s, 3H), 3.06 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.93, 147.38, 136.48, 135.26, 130.52, 128.79, 128.71, 128.63, 127.08, 126.82, 126.08, 37.92, 36.12, 30.54. IR (neat): 3058, 3017, 2918, 2846, 1640, 1601, 1557, 1496, 1488, 1472, 1449, 1426, 1360, 1335, 1236, 1182, 1148, 1122, 1074, 1065, 1045, 1026, 979, 966, 919, 898, 866, 789, 777, 760, 719, 696, 688, 669 cm⁻¹; HRMS (ESI) calcd for C₁₈H₁₉N₂O₃S [M+H]⁺: 343.1111, found 343.1114.




***N*-Methyl-*N*-(5-pentyl-2-phenyloxazol-4-yl)methanesulfonamide (3t).** Following the typical procedure, 0.3 mmol scale, 63.8 mg **2c**, 61.0 mg **1t**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 20:1) afforded the title product as a colorless oil in 30% (29 mg) yield. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.98-7.95 (m, 2H), 7.45-7.43 (m, 3H), 3.27 (s, 3H), 3.03 (s, 3H), 2.78 (t, *J* = 7.2 Hz, 2H), 1.74-1.68 (m, 2H), 1.40-1.36 (m, 4H), 0.93-0.90 (m, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.32, 149.52, 134.60, 130.32, 128.72, 127.34, 125.96, 37.94, 36.02, 31.35, 27.10, 24.27, 22.27, 13.93. IR (neat): 2954, 2929, 2859, 1640, 1559, 1488, 1450, 1345, 1192, 1150, 1066, 1042, 1025, 962, 861, 775, 724, 691, 675 cm⁻¹; HRMS (ESI) calcd for C₁₆H₂₃N₂O₃S[M+H]⁺: 323.1424, found 323.1427.



***N*-(5-Cyclopropyl-2-phenyloxazol-4-yl)-*N*-phenylmethanesulfonamide (3u).** 0.3 mmol scale. Following the typical procedure, 63.8 mg **2c**, 70.6 mg **1u**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 2 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 89% (94.8 mg) isolated yield. M.p. 127-129 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.98-7.95 (m, 2H), 7.67 (d, *J* = 8.0 Hz, 2H), 7.44-7.36 (m, 5H), 7.32-7.28 (m, 1H), 3.24 (s, 3H), 2.06-1.99 (m, 1H), 1.03-0.99 (m, 4H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 157.05, 150.13, 140.59, 133.93, 130.24, 129.21, 128.63, 127.58, 127.17, 127.11, 125.89, 38.44, 6.90, 5.81. IR (neat): 3050, 3018, 2928, 2850, 1639, 1595, 1557, 1485, 1450, 1410, 1394, 1347, 1327, 1284, 1246, 1207, 1164, 1150, 1115, 1096, 1072, 1057, 1047, 1030, 1006, 964, 949, 912, 904, 870, 846, 816, 788, 771, 761, 724, 710, 699, 685 cm⁻¹; HRMS (ESI) calcd for C₁₉H₁₉N₂O₃S [M+H]⁺: 355.1111, found 355.1112.




***N*-(2-(4-Fluorophenyl)-5-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3v).** 0.3 mmol scale. Following the typical procedure, 70.3 mg 3-(4-fluorophenyl)-5,5-dimethyl-1,4,2-dioxazole **2d**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 80 °C for 4 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:0 to 3:1:1) afforded the title product as a white solid in 90% (93.1 mg) isolated yield. M.p. 188-190 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.06-8.03 (m, 2H), 7.99 (d, *J* = 7.6 Hz, 2H), 7.47-7.43 (m, 2H), 7.37-7.33 (m, 1H), 7.18-7.14 (m, 2H), 3.31 (s, 3H), 3.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 164.18 (d, ¹*J*_{C-F} = 250.9 Hz), 157.45, 145.31, 134.64, 128.98, 128.75, 128.37 (d, ³*J*_{C-F} = 8.8 Hz), 126.62, 125.16, 123.18 (d, ⁴*J*_{C-F} = 3.0 Hz), 116.02 (d, ²*J*_{C-F} = 22.4 Hz), 37.83, 36.83. IR (neat): 3066, 3021, 2933, 1611, 1600, 1501, 1463, 1453, 1416, 1365, 1338, 1325, 1286, 1228, 1188, 1154, 1144, 1101, 1090, 1062, 1033, 1012, 994, 973, 961, 951, 927, 853, 815, 764, 746, 721, 696 cm⁻¹; HRMS (ESI) calcd for C₁₇H₁₆FN₂O₃S [M+H]⁺: 347.0860, found 347.0861.




***N*-(2-(4-Chlorophenyl)-5-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3w).** 0.3 mmol scale. Following the typical procedure, 76.2 mg 3-(4-chlorophenyl)-5,5-dimethyl-1,4,2-dioxazole **2e**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 80 °C for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:1) afforded the title product as a white solid in 93% (101.6 mg) isolated yield. M.p. 215-217 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.00 (m, 4H), 7.46-7.37 (m, 5H), 3.32 (s, 3H),

3.20 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.36, 145.57, 136.88, 134.76, 129.15, 128.81, 127.48, 126.57, 125.32, 125.26, 37.88, 36.89. IR (neat): 3070, 3022, 2933, 1611, 1600, 1501, 1463, 1453, 1416, 1365, 1338, 1325, 1286, 1228, 1188, 1154, 1144, 1101, 1090, 1062, 1033, 1012, 1003, 994, 973, 961, 951, 927, 853, 815, 764, 746, 721, 696 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{ClN}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 363.0565, found 363.0566.




***N*-Methyl-*N*-(5-phenyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methanesulfonamide (**3x**).**


0.3 mmol scale. Following the typical procedure, 88.3 mg 5,5-dimethyl-3-(4-(trifluoromethyl)phenyl)-1,4,2-dioxazole **2f**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at 80 $^\circ\text{C}$ for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:0 to 3:1:1) afforded the title product as a white solid in 77% (92.1 mg) isolated yield. M.p. 190-192 $^\circ\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.17 (d, J = 8.4 Hz, 2H), 8.03-8.01 (m, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.49-7.45 (m, 2H), 7.40-7.37 (m, 1H), 3.33 (s, 3H), 3.21 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 156.82, 146.23, 134.99, 132.23 (q, $^2J_{\text{C-F}}$ = 32.6 Hz), 129.96 (q, $^5J_{\text{C-F}}$ = 1.1 Hz), 129.38, 128.87, 126.47, 126.41, 125.84 (q, $^3J_{\text{C-F}}$ = 3.8 Hz), 125.40, 123.71 (q, $^1J_{\text{C-F}}$ = 271.4 Hz), 37.87, 36.89. IR (neat): 3018, 2925, 2850, 1618, 1600, 1563, 1496, 1448, 1415, 1373, 1347, 1322, 1239, 1186, 1156, 1114, 1093, 1070, 1060, 1033, 1016, 1005, 993, 973, 950, 920, 859, 851, 779, 765, 730, 701, 690, 683 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{F}_3\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 397.0828, found 397.0830.




***N*-(2-(4-Methoxyphenyl)-5-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3y).** 0.3 mmol scale. Following the typical procedure, 74.6 mg 3-(4-methoxyphenyl)-5,5-dimethyl-1,4,2-dioxazole **2g**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 80 °C for 4 h. Column chromatography on silica gel (wet loading, eluent: petroleum ether: ethyl acetate = 5:1 to petroleum ether: ethyl acetate: dichloromethane = 2:1:1) afforded the title product as a white solid in 92% (98.8 mg) isolated yield. M.p. 199-201 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.99 (d, *J* = 7.2 Hz, 4H), 7.45-7.44 (m, 2H), 7.37-7.35 (d, *J* = 6.8 Hz, 1H), 6.99 (d, *J* = 7.6 Hz, 2H), 3.87 (s, 3H), 3.32 (s, 3H), 3.21 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 161.68, 158.50, 144.66, 134.57, 128.76, 127.98, 126.96, 125.11, 119.64, 114.24, 55.39, 37.92, 36.90. IR (neat): 3023, 2950, 1615, 1596, 1583, 1500, 1464, 1453, 1439, 1421, 1367, 1342, 1322, 1306, 1284, 1256, 1196, 1175, 1152, 1118, 1100, 1064, 1028, 1004, 997, 972, 965, 909, 858, 834, 806, 798, 772, 762, 743, 721, 691 cm⁻¹; HRMS (ESI) calcd for C₁₈H₁₉N₂O₄S [M+H]⁺: 359.1060, found 359.1062.



***N*-Methyl-*N*-(5-phenyl-2-(*o*-tolyl)oxazol-4-yl)methanesulfonamide (3z).** 0.3 mmol scale. Following the typical procedure, 68.8 mg 5,5-dimethyl-3-(*o*-tolyl)-1,4,2-dioxazole **2h**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 80 °C for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:0 to 3:1:1) afforded the title product as a white solid in 90% (92.0 mg) isolated yield. M.p. 154-156 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.05 (d, *J* = 7.6 Hz, 1H), 8.01 (d, *J* = 7.6 Hz, 2H), 7.47-7.43 (m, 2H), 7.37-7.29 (m, 4H), 3.32 (s, 3H), 3.20 (s, 3H), 2.72 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.59, 144.66, 137.35, 134.40, 131.74, 130.35, 128.89, 128.76, 128.43, 126.76, 126.04, 125.57, 125.19, 37.93, 36.62, 22.09. IR (neat): 3018, 2924, 2853, 1616, 1596, 1536, 1495, 1462, 1448, 1362, 1342, 1319, 1239, 1181, 1156, 1139, 1091, 1066, 1045, 1033, 1002, 995, 958, 916, 872, 847, 804, 773, 757, 734, 721, 697, 687, 668 cm⁻¹; HRMS (ESI) calcd for C₁₈H₁₉N₂O₃S [M+H]⁺: 343.1111, found 343.1112.




***N*-(2-(6-Chloropyridin-3-yl)-5-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3za).** 0.2 mmol scale. Following the typical procedure, 51.0 mg 3-(6-chloropyridin-3-yl)-5,5-dimethyl-1,4,2-dioxazole **2i**, 41.9 mg **1a**, 2 mL DCE, 8.7 mg IPrAuNTf₂ were stirred at 80 °C for 5 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:1 to 3:1:1) afforded the title product as a white solid in 75% (54.4 mg) isolated yield. M.p. 214-216 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 9.05 (d, *J* = 2.0 Hz, 1H), 8.27 (dd, *J* = 8.4, 2.2 Hz, 1H), 8.00 (d, *J* = 7.6 Hz, 2H), 7.50-7.46 (m, 3H), 7.42-7.38 (m, 1H), 3.33 (s, 3H), 3.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 155.09, 153.27, 147.47, 146.42, 135.85, 134.95, 129.54, 128.93, 126.18, 125.42, 124.51, 122.10, 37.87, 36.98. IR (neat): 3062, 3006, 2933, 1612, 1600, 1567, 1495, 1463, 1450, 1372, 1343, 1322, 1288, 1236, 1157, 1147, 1130, 1109, 1062, 1032, 1022, 1003, 992, 961, 951, 857, 841, 771, 758, 743, 729, 705, 687 cm⁻¹; HRMS (ESI) calcd for C₁₆H₁₅ClN₃O₃S [M+H]⁺: 364.0517, found 364.0519.




***N*-(2-(Furan-2-yl)-5-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3zb).** 0.3 mmol scale. Following the typical procedure, 60.2 mg 3-(furan-2-yl)-5,5-dimethyl-1,4,2-dioxazole **2j**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 80 °C for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:0 to 3:1:1) afforded the title product as a white solid in 95% (91.0 mg) isolated yield. M.p. 150-152 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.00 (s, 2H), 7.59-7.37 (m, 4H), 7.09 (s, 1H), 6.57 (s, 1H), 3.32 (s, 3H), 3.18 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 151.10, 144.87, 144.84, 142.17, 134.20, 129.07, 128.71, 126.33, 125.21, 112.25, 111.96, 37.72, 36.84. IR (neat):

3118, 3024, 2937, 1638, 1618, 1598, 1528, 1495, 1450, 1410, 1360, 1337, 1234, 1184, 1173, 1153, 1139, 1112, 1072, 1063, 1035, 1014, 1004, 993, 966, 922, 898, 885, 871, 836, 822, 769, 750, 708, 690 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$: 319.0747, found 319.0750.




***N*-Methyl-*N*-(5-phenyl-2-(thiophen-2-yl)oxazol-4-yl)methanesulfonamide (3zc).** 0.3 mmol scale. Following the typical procedure, 66.0 mg 5,5-dimethyl-3-(thiophen-2-yl)-1,4,2-dioxazole **2k**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at 80 °C for 2 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:1) afforded the title product as a white solid in 95% (95.5 mg) isolated yield. M.p. 156-158 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.98 (d, J = 7.6 Hz, 2H), 7.72 (d, J = 2.8 Hz, 1H), 7.46-7.43 (m, 3H), 7.37-7.34 (m, 1H), 7.14-7.11 (m, 1H), 3.30 (s, 3H), 3.18 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 154.60, 144.75, 134.39, 129.27, 128.96, 128.89, 128.74, 128.19, 128.01, 126.52, 125.17, 37.84, 36.88. IR (neat): 3103, 3015, 2937, 2850, 1612, 1572, 1508, 1495, 1448, 1420, 1372, 1348, 1334, 1319, 1274, 1239, 1202, 1174, 1151, 1072, 1051, 1043, 1029, 1003, 990, 973, 955, 924, 851, 834, 773, 760, 730, 705, 686, 660 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}_3\text{S}_2$ $[\text{M}+\text{H}]^+$: 335.0519, found 335.0521.




***N*-Methyl-*N*-(2-(naphthalen-2-yl)-5-phenyloxazol-4-yl)methanesulfonamide (3zd).** 0.3 mmol scale. Following the typical procedure, 81.8 mg 5,5-dimethyl-3-(naphthalen-2-yl)-1,4,2-dioxazole **2l**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at 80 °C for 2 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane


= 5:1:0 to 2:1:1) afforded the title product as a white solid in 97% (110.3 mg) isolated yield. M.p. 197-199 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 8.50 (s, 1H), 8.10-8.04 (m, 3H), 7.93-7.88 (m, 2H), 7.84-7.82 (m, 1H), 7.53-7.44 (m, 4H), 7.38-7.34 (m, 1H), 3.34 (s, 3H), 3.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.37, 145.36, 134.79, 134.16, 132.80, 128.95, 128.75, 128.62, 128.59, 127.80, 127.42, 126.83, 126.73, 126.16, 125.23, 124.00, 122.89, 37.88, 36.88. IR (neat): 3052, 2934, 1695, 1614, 1547, 1509, 1494, 1447, 1340, 1327, 1320, 1234, 1178, 1155, 1085, 1072, 1058, 1030, 1005, 995, 966, 937, 916, 900, 892, 862, 835, 824, 766, 754, 732, 710, 687 cm⁻¹; HRMS (ESI) calcd for C₂₁H₁₉N₂O₃S [M+H]⁺: 379.1111, found 379.1112.



(E)-N-Methyl-N-(5-phenyl-2-styryloxazol-4-yl)methanesulfonamide (3ze). 0.3 mmol scale. Following the typical procedure, 73.2 mg (*E*)-5,5-dimethyl-3-styryl-1,4,2-dioxazole **2m**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 80 °C for 2 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: dichloromethane = 5:1:0 to 2:1:1) afforded the title product as a white solid in 97% (103.2 mg) isolated yield. M.p. 192-194 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.99 (d, *J* = 7.6 Hz, 2H), 7.56-7.53 (m, 3H), 7.45-7.32 (m, 6H), 6.87 (d, *J* = 16.4 Hz, 1H), 3.28 (s, 3H), 3.16 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.04, 144.83, 136.74, 135.00, 134.64, 129.37, 128.91, 128.80, 128.67, 127.13, 126.59, 125.17, 113.07, 37.71, 36.70. IR (neat): 3050, 3007, 2926, 2850, 1643, 1621, 1597, 1578, 1535, 1495, 1463, 1448, 1365, 1336, 1321, 1239, 1210, 1180, 1165, 1150, 1070, 1033, 1008, 975, 917, 861, 846, 785, 755, 729, 685 cm⁻¹; HRMS (ESI) calcd for C₁₉H₁₉N₂O₃S [M+H]⁺: 355.1111, found 355.1113.




***N*-Methyl-*N*-(2-methyl-5-phenyloxazol-4-yl)methanesulfonamide (3zf).** 0.3 mmol scale. Following the typical procedure, 74.6 mg (1*R*,3*S*,5*r*,7*r*)-3'-methylspiro[adamantane-2,5'-[1,4,2]dioxazole] **2n**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at room temperature for 10 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 2:1) afforded the title product as a white solid in 71% (56.7 mg) isolated yield. M.p. 140-142 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.89 (d, *J* = 7.6 Hz, 2H), 7.44-7.40 (m, 2H), 7.36-7.32 (m, 1H), 3.25 (s, 3H), 3.13 (s, 3H), 2.50 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 158.70, 145.27, 133.02, 128.76, 128.73, 126.80, 125.01, 37.79, 36.81, 14.30. IR (neat): 3004, 2925, 2853, 1627, 1583, 1494, 1450, 1387, 1358, 1336, 1321, 1297, 1275, 1239, 1176, 1149, 1133, 1102, 1067, 1035, 1003, 994, 976, 921, 853, 774, 725, 712, 691, 673, 666 cm⁻¹; HRMS (ESI) calcd for C₁₂H₁₅N₂O₃S [M+H]⁺: 267.0798, found 267.0801.




***N*-(2-Cyclohexyl-5-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide (3zg).** 0.3 mmol scale. Following the typical procedure, 66.0 mg 3-cyclohexyl-5,5-dimethyl-1,4,2-dioxazole **2o**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf₂ were stirred at 80 °C for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 94% (94.4 mg) isolated yield. M.p. 110-112 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.91-7.89 (m, 2H), 7.43-7.39 (m, 2H), 7.33-7.30 (m, 1H), 3.25 (s, 3H), 3.13 (s, 3H), 2.84-2.76 (m, 1H), 2.12-2.08 (m, 2H), 1.86-1.82 (m, 2H), 1.74-1.71 (m, 1H), 1.66-1.56 (m, 2H), 1.45-1.25 (m, 3H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 165.16, 144.35, 132.76, 128.54, 128.46, 126.94, 124.88, 37.69, 37.53, 36.72, 30.27, 25.52, 25.34. IR (neat): 3010, 2936, 2857, 1626, 1565, 1496, 1470, 1448, 1358, 1341, 1325, 1241, 1201, 1179, 1149, 1077, 1028, 1003, 992,

972, 893, 866, 844, 718, 774, 756, 734, 715, 693 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{23}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 335.1424, found 335.1425.




***N*-(2-((3*r*,5*r*,7*r*)-Adamantan-1-yl)-5-phenyloxazol-4-yl)-*N*-methylmethanesulfonamide**

(3zh). 0.3 mmol scale. Following the typical procedure, 84.7 mg 3-((3*r*,5*r*,7*r*)-adamantan-1-yl)-5,5-dimethyl-1,4,2-dioxazole **2p**, 62.8 mg **1a**, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at 80 °C for 3 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 5:1) afforded the title product as a white solid in 96% (111.4 mg) isolated yield. M.p. 163-165 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.91-7.89 (m, 2H), 7.43-7.39 (m, 2H), 7.33-7.29 (m, 1H), 3.25 (s, 3H), 3.13 (s, 3H), 2.10 (bs, 3H), 2.07-2.06 (m, 6H), 1.83-1.76 (m, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 167.81, 144.05, 132.84, 128.56, 128.42, 127.14, 124.93, 40.14, 37.78, 36.85, 36.29, 35.75, 27.81. IR (neat): 3018, 2905, 2851, 1626, 1555, 1495, 1449, 1360, 1340, 1325, 1273, 1237, 1152, 1101, 1072, 1004, 994, 969, 954, 865, 834, 772, 760, 714, 690, 677 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{27}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 387.1737, found 387.1739.




Ethyl 2,4-diphenyloxazole-5-carboxylate (6). 0.3 mmol scale. Following the typical procedure, 63.8 mg 5,5-dimethyl-3-phenyl-1,4,2-dioxazole **2c**, 52.3 mg ethyl 3-phenylpropiolate, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at 80 °C for 24 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 40:1) afforded the title product as a white solid in 51% (44.8 mg) isolated yield. M.p. 123-125 °C. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.22-8.20 (m, 2H), 8.13-8.11 (m, 2H), 7.54-7.41 (m, 6H), 4.41 (q, J = 7.2 Hz, 2H), 1.39 (t, J = 7.2 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 162.06, 158.63, 147.92, 136.31, 131.53, 130.40, 129.58, 129.40, 128.82, 128.03, 127.33, 126.32, 61.36, 14.19. IR (neat): 3050, 2978, 2924, 2850, 1706, 1608, 1591, 1583, 1566, 1545, 1492, 1481, 1448, 1397, 1375,

1355, 1317, 1304, 1289, 1244, 1184, 1160, 1138, 1113, 1091, 1072, 1037, 1024, 990, 954, 926, 870, 835, 783, 760, 720, 711, 686, 675 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{NO}_3$ $[\text{M}+\text{H}]^+$: 294.1125, found 294.1126.



(2,4-Diphenyloxazol-5-yl)(phenyl)methanone (7). 0.3 mmol scale. Following the typical procedure, 63.8 mg 5,5-dimethyl-3-phenyl-1,4,2-dioxazole **2c**, 61.9 mg 1,3-diphenylprop-2-yn-1-one, 3 mL DCE, 13.0 mg IPrAuNTf_2 were stirred at 80 $^{\circ}\text{C}$ for 24 h. Column chromatography on silica gel (eluent: petroleum ether: ethyl acetate = 10:1) afforded the title product as a white solid in 50% (48.8 mg) isolated yield. M.p. 147-149 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 8.19-8.17 (m, 2H), 8.10-8.08 (m, 2H), 7.96 (d, $J = 7.2$ Hz, 2H), 7.60-7.41 (m, 9H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 183.14, 161.91, 148.81, 143.43, 137.49, 132.85, 131.73, 130.56, 129.82, 129.55, 129.28, 128.96, 128.33, 128.19, 127.40, 126.26. IR (neat): 3057, 1649, 1598, 1576, 1549, 1529, 1488, 1476, 1451, 1444, 1359, 1321, 1292, 1302, 1232, 1162, 1072, 1027, 1013, 998, 976, 959, 935, 894, 796, 783, 730, 716, 696, 686, 673 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 326.1176, found 326.1175.

Synthesis of compound 13.




To a solution of 5,5-dimethyl-3-(*o*-tolyl)-1,4,2-dioxazole (1.91 g, 10 mmol) in CCl_4 (30 mL) were added NBS (1.96 g, 11 mmol) and BPO (75%, wetted with ca. 25% Water, 484.5 mg,


1.5 mmol). The resulting solution was refluxed at 100 °C for 5 h. Then the mixture was quenched with saturated NaHCO₃ solution, extracted with dichloromethane, and dried over anhydrous Na₂SO₄. The solvent was evaporated under the reduced pressure and the residue was used directly for the next step.

To a solution of the above substrate in EtOH (20 mL) was added KSCN (1.26 g, 13 mmol). The resulting solution was stirred at 80 °C for 0.5 h. Then the reaction mixture was filtered through a pad of silica gel using ethyl acetate as an eluent. The filtrate was collected and evaporated under reduced pressure, the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: = 10:1) to afford compound **s1-13** (1.68 g, 68%) as a white solid.

To a solution of *N*-ethynyl-4-methyl-*N*-phenylbenzenesulfonamide **s2-13** (976.8 mg, 3.6 mmol) in THF (15 mL) was added *n*-BuLi (1.44 mL, 3.6 mmol, 2.5 M in hexanes) at -78 °C. After stirring at the same temperature for 30 min, **s1-13** (744.9 mg, 3 mmol, dissolved in 5 mL THF) was added at -78 °C. Then the dry-ice/ acetone bath was removed. The reaction mixture was warmed up to room temperature and stirred for 3 h. Then the resulting mixture was quenched with saturated ammonium chloride solution, extracted with ethyl acetate, and dried over anhydrous Na₂SO₄. The solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (eluent: petroleum ether: ethyl acetate: = 10:1) to afford compound **13** (1.05 g, 71%) as a yellow oil.




5,5-Dimethyl-3-(2-(thiocyanatomethyl)phenyl)-1,4,2-dioxazole (s1-13). M.p. 109-111 °C. ¹H NMR (400 MHz, CDCl₃, Me₄Si) δ 7.83 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.54-7.44 (m, 3H), 4.46 (s, 2H), 1.70 (s, 6H); ¹³C NMR (100 MHz, CDCl₃, Me₄Si) δ 157.22, 134.97, 131.40, 131.03, 129.10, 128.93, 121.76, 114.93, 113.27, 38.20, 24.71. IR (neat): 3076, 2992, 2938, 2155, 1711, 1607, 1594, 1568, 1498, 1453, 1420, 1385, 1373, 1351, 1287, 1249, 1215, 1169, 1116, 1063, 1046, 976, 948, 893, 842, 819, 781, 768, 711, 680, 660 cm⁻¹; HRMS (ESI) calcd for C₁₂H₁₃N₂O₂S [M+H]⁺: 249.0692, found 249.0695.



***N*-(((2-(5,5-Dimethyl-1,4,2-dioxazol-3-yl)benzyl)thio)ethynyl)-4-methyl-*N*-phenylbenzenesulfonamide (**13**).** ^1H NMR (400 MHz, CDCl_3 , Me_4Si) δ 7.76 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.56-7.54 (m, 2H), 7.37-7.25 (m, 7H), 7.15 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.11-7.08 (m, 2H), 4.19 (s, 2H), 2.43 (s, 3H), 1.67 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3 , Me_4Si) δ 157.53, 144.93, 138.87, 136.67, 133.08, 131.19, 130.54, 129.44, 129.04, 128.87, 128.18, 127.99, 127.59, 125.97, 121.92, 114.58, 89.34, 65.19, 40.37, 24.72, 21.62. IR (neat): 3062, 2990, 2931, 2159, 1717, 1594, 1570, 1488, 1454, 1372, 1348, 1307, 1266, 1216, 1187, 1172, 1089, 1063, 1045, 979, 948, 922, 888, 814, 767, 735, 703, 691, 661 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{24}\text{N}_2\text{NaO}_4\text{S}_2$ $[\text{M}+\text{Na}]^+$: 515.1070, found 515.1069.


Trapping of α -imino gold-carbene intermediate.



To a solution of **13** (147.8 mg, 0.3 mmol) in THF (3 mL) was added IPrAuNTf_2 (13.0 mg, 0.015 mmol) at room temperature. After stirring for 5 h. The solvent was evaporated under the reduced pressure and the residue was purified by chromatography on silica gel (eluent: petroleum ether: ethyl acetate: = 2:1) to afford compound **15** (90.9 mg, 70%) as a white solid. M.p. 268-270 $^\circ\text{C}$. ^1H NMR (400 MHz, $\text{DMSO}-d_6$, Me_4Si , 80 $^\circ\text{C}$) δ 9.67 (bs, 1H), 7.83 (d, $J = 5.6$ Hz, 1H), 7.65 (d, $J = 5.6$ Hz, 2H), 7.34 (d, $J = 5.6$ Hz, 2H), 7.31-7.27 (m, 4H), 7.20-7.17 (m, 1H), 7.12 (td, $J = 5.2, 1.2$ Hz, 1H), 6.86 (d, $J = 4.8$ Hz, 1H), 4.32 (bs, 2H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$, Me_4Si , 80 $^\circ\text{C}$) δ 171.17, 145.05, 136.29, 135.06, 132.88, 131.37, 130.07, 129.74, 129.13, 128.38, 127.05, 127.02, 126.35, 125.37, 125.33, 123.26, 118.57, 113.62, 109.44, 32.16, 20.55. IR (neat): 3197, 2923, 2848, 1690, 1663, 1589, 1494, 1448, 1371,


1335, 1314, 1294, 1245, 1215, 1189, 1172, 1123, 1098, 1027, 951, 815, 796, 775, 766, 753, 737, 702, 670 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{19}\text{N}_2\text{O}_3\text{S}_2$ $[\text{M}+\text{H}]^+$: 435.0832, found 435.0832.

Gram scale synthesis of oxazole 3a.



To a solution of 5,5-dimethyl-3-phenyl-1,4,2-dioxazole **2c** (1.06 g, 6 mmol) and ynamide **1a** (1.05 g, 5 mmol) in DCE (20 mL) was added IPrAuNTf_2 (86.6 mg, 0.1 mmol). After the reaction mixture was stirred at room temperature for 6 h, the solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether: ethyl acetate = 5:1) to afford **3a** (1.47 g, 89%) as a white solid.

Detection of the released acetone.



To a solution of 5,5-dimethyl-3-phenyl-1,4,2-dioxazole **2c** (63.8 mg, 0.36 mmol) and ynamide **1a** (62.8 mg, 0.3 mmol) in DCE (1 mL) was added IPrAuNTf_2 (13.0 mg, 0.015 mmol). After the reaction mixture was stirred at room temperature for 2 h, 21 μL CH_2Br_2 was added. The ^1H NMR of the crude reaction mixture revealed that **3a** was formed in 98% NMR yield, and acetone was formed in 99% NMR yield.

References:

- [1] P. Braunstein, H. Lehner, D. Matt, *Inorg. Synth.* **1990**, 27, 218.
- [2] N. Mézailles, L. Ricard, F. Gagosz, *Org. Lett.* **2005**, 7, 4133.
- [3] L. Ricard, F. Gagosz, *Organometallics* **2007**, 26, 4704.
- [4] P. de Frémont, N. Marion, S. P. Nolan, *J. Organomet. Chem.* **2009**, 694, 551.
- [5] A. Collado, A. Gómez-Suárez, A. R. Martín, A. M. Z. Slawin, S. P. Nolan, *Chem. Commun.* **2013**, 49, 5541.

- [6] A. Vij, Y. Y. Zheng, R. L. Kirchmeier, J. M. Shreeve, *Inorg. Chem.* **1994**, 33, 3281.
- [7] L. Zhu, Y. Yu, Z. Mao, X. Huang, *Org. Lett.* **2015**, 17, 30.
- [8] B. Yao, Z. Liang, T. Niu, Y. Zhang, *J. Org. Chem.* **2009**, 74, 4630.
- [9] L. Li, C. Shu, B. Zhou, Y.-F. Yu, X.-Y. Xiao, L.-W. Ye, *Chem. Sci.* **2014**, 5, 4057.
- [10] C. Shu, Y.-H. Wang, B. Zhou, X.-L. Li, Y.-F. Ping, X. Lu, L.-W. Ye, *J. Am. Chem. Soc.* **2015**, 137, 9567.
- [11] A. Mukherjee, R. B. Dateer, R. Chaudhuri, S. Bhunia, S. N. Karad, R.-S. Liu, *J. Am. Chem. Soc.* **2011**, 133, 15372.
- [12] R. Guo, H. Yang, P. Tang, *Chem. Commun.*, **2015**, 51, 8829.
- [13] R. B. Dateer, K. Pati, R.-S. Liu, *Chem. Commun.* **2012**, 48, 7200.
- [14] M. Garzón, P. W. Davies, *Org. Lett.* **2014**, 16, 4850.
- [15] Y. Park, K. T. Park, J. G. Kim, S. Chang, *J. Am. Chem. Soc.* **2015**, 137, 4534.
- [16] X-A. Gao, X-X Wang, H. Yan, J. Li, R-L. Yan, G-S. Huang, *J. Indian Chem. Soc.* **2013**, 90, 381.

X-ray crystal structure of compounds IPrAuNTf₂, 3b, 15.




Figure 1. X-ray crystal structure of IPrAuNTf₂




Figure 2. X-ray crystal structure of compound **3b**











Figure 3. X-ray crystal structure of compound **15**





^1H NMR (400 MHz, CD_2Cl_2)





^{13}C NMR (100 MHz, CD_2Cl_2)






¹H NMR (400 MHz, CDCl₃)




¹³C NMR (100 MHz, CDCl₃)



^1H NMR (400 MHz, CDCl_3)




¹³C NMR (100 MHz, CDCl₃)






138.603
131.479
129.426
128.289
128.259
128.147
125.492
122.154

81.945
77.320
77.000
76.680
70.858



36.732






¹H NMR (400 MHz, CDCl₃)




¹³C NMR (100 MHz, CDCl₃)



¹H NMR (400 MHz, CDCl₃)




¹³C NMR (100 MHz, CDCl₃)






138.559
134.651
132.204
131.509
129.612
129.256
129.232
128.521
128.320
128.207
126.204
122.198



82.354
77.315
77.000
76.685
70.733







¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)



¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)




3.805

3.121




0.000





¹³C NMR (100 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)







¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)



¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)



¹H NMR (400 MHz, CDCl₃)

7.563
7.542
7.493
7.491
7.472
7.469
7.270

3.323
3.140



¹³C NMR (100 MHz, CDCl₃)

131.055
129.772
129.446
129.119
128.801
127.912
126.387
125.202
125.180
125.142
125.104
125.066
122.500
119.790

85.411

77.319



77.000

76.681



68.604

39.007



36.965






¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)







^1H NMR (400 MHz, CDCl_3)






¹³C NMR (100 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃)




^{13}C NMR (100 MHz, CDCl_3)



^1H NMR (400 MHz, CDCl_3)



s3-1o




^{13}C NMR (100 MHz, CDCl_3)

220.581


140.677
136.498
132.453
129.270
125.254
119.238

83.626
77.320
77.000
76.688
76.457





50.281
47.768
44.243
37.736
35.691
31.371
28.917
26.128
25.407
21.428
13.687



s3-1o



^1H NMR (400 MHz, CDCl_3)





^{13}C NMR (100 MHz, CDCl_3)

220.700





140.685
136.625
132.401
129.218
125.359
119.923

80.012
77.320
77.000
76.680




50.400
48.757
47.872
44.377
37.825
35.788
31.467
29.006
26.225
25.481
21.525
13.776







^1H NMR (400 MHz, CDCl_3)






^{13}C NMR (100 MHz, CDCl_3)





^1H NMR (400 MHz, CDCl_3)



¹³C NMR (100 MHz, CDCl₃)



¹H NMR (400 MHz, CDCl₃)



¹³C NMR (100 MHz, CDCl₃)



133.286
128.006
126.965
122.206

86.355





77.320
77.000
76.680

62.715



39.119
36.963



¹H NMR (400 MHz, CDCl₃)



¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)

7.321
7.311
7.233
7.226

3.695

3.174
3.023


-0.000





5/15

2/00



3/17
3.13






¹³C NMR (100 MHz, CDCl₃)







¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)



¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)





1.664



0.000





¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)



¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)






S100



¹³C NMR (100 MHz, CDCl₃)



¹H NMR (400 MHz, CDCl₃)




¹³C NMR (100 MHz, CDCl₃)





S103



¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)






¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)



¹³C NMR (100 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃)




2.569

1.684

-0.000




^{13}C NMR (100 MHz, CDCl_3)





S111

¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)





S113



¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)



¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)



1.645



-0.000





6.12





¹³C NMR (100 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (100 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃)







2p




¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)



¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)





3.327




-0.000





¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)






^{13}C NMR (100 MHz, CDCl_3)






^1H NMR (400 MHz, CDCl_3)






^{13}C NMR (100 MHz, CDCl_3)






^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)






^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)






¹H NMR (400 MHz, CDCl₃)




^{13}C NMR (100 MHz, CDCl_3)




^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)






0.000






¹³C NMR (100 MHz, CDCl₃)






^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)






¹³C NMR (100 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)






^{13}C NMR (100 MHz, CDCl_3)






^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)







^1H NMR (400 MHz, CDCl_3)






¹³C NMR (100 MHz, CDCl₃)







¹H NMR (400 MHz, CDCl₃)






^{13}C NMR (100 MHz, CDCl_3)







¹H NMR (400 MHz, CDCl₃)





^{13}C NMR (100 MHz, CDCl_3)







^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)






¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)








^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)







^1H NMR (400 MHz, CDCl_3)






^{13}C NMR (100 MHz, CDCl_3)




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (100 MHz, CDCl₃)






¹H NMR (400 MHz, CDCl₃)





^{13}C NMR (100 MHz, CDCl_3)





^1H NMR (400 MHz, CDCl_3)





^{13}C NMR (100 MHz, CDCl_3)





¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)






¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)






¹³C NMR (100 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (100 MHz, CDCl₃)






^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)







^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)








^1H NMR (400 MHz, CDCl_3)



¹³C NMR (100 MHz, CDCl₃)



^1H NMR (400 MHz, CDCl_3)



¹³C NMR (100 MHz, CDCl₃)

167.805

144.050

132.842

128.564

128.420

127.141

124.928

77.319

77.000

76.681

40.139



37.782

36.848






36.290

35.748



27.808




^1H NMR (400 MHz, CDCl_3)





¹³C NMR (100 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)



¹³C NMR (100 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




4.461

1.698


0.000




s1-13






¹³C NMR (100 MHz, CDCl₃)





s1-13



^1H NMR (400 MHz, CDCl_3)






¹³C NMR (100 MHz, CDCl₃)







S203

^1H NMR (400 MHz, DMSO- d_6 , Me $_4$ Si, 80 °C)



¹³C NMR (400 MHz, DMSO-*d*₆, 80 °C)



S205